Audit: QRS - Chinese Rhubarb for Health & Longevity

Audit conducted on 04/09/2026 06:00 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every protocol cell, gate item, tier item, marker row and qualitative item traces to an ER passage (ER Therapeutic Protocol, Key Interactions & Contraindications, Expected Benefits, Potential Risks & Side Effects, Monitoring Protocol & Defining Success, Practical Considerations, Conclusion).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	marker_9_target carries the ER’s own hedge verbatim: “No established target — record presence, absence and extent, and track change against the individual’s own prior colonoscopy” (ER line 496).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication thresholds and staging are carried at ER strength (potassium below 3.5 mmol/L, Child-Pugh B or C, CKD stage 4 or 5); no gate is downgraded to a caution or vice versa.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefits come only from Expected Benefits, risks only from Potential Risks & Side Effects, gates only from Key Interactions & Contraindications; no modifying-factor bullet was promoted into a gate or a tier.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names, URLs or brand names anywhere in the QRS body.
1.6	The QRS does not introduce new attributions.	🟢	The only attribution is “European medicines regulators” in at_a_glance, taken from the ER Conclusion (“European medicines regulators accept it on that basis”).

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The sceptical, conflict-aware register of the ER Conclusion is carried into at_a_glance and the tier lists.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Decision-enabling framing: one validated use stated plainly, weak claims flagged, harms tied to duration.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Cells and cadence text are nominal descriptions of what the evidence supports, not orders to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, or “take” directed at a reader; the footer disclaimer is intact.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	monitoring_cadence presents intervals as facts (“no ongoing testing is warranted”, “potassium and magnesium at four weeks”) rather than recommendations.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms present (hypokalemia, melanosis coli, hepatic encephalopathy) are the ER’s own condition names and are not replaceable without losing the fact.
2.8	Information is presented in a concise and very compact manner	🟢	Every entry is a noun phrase or short clause; no mechanistic sentences, no effect sizes, no citations.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by search: no “you”/”your” in the document.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The monitoring panel, oxalate threshold and duration ceilings address a self-directed, testing-oriented reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	10-marker monitoring panel including a 24-hour urine collection and colonoscopy pigmentation tracking assumes a high-effort reader.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges (potassium 4.0–4.5 mmol/L, ALT below 25/20 U/L) are tighter than conventional lab ranges, which is a longevity-audience framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	at_a_glance foregrounds that harms scale with duration — the exact axis on which a longevity user’s exposure differs from occasional use.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not appear; the header topic reads “Chinese Rhubarb for Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terms used throughout (“hydroxyanthracene derivatives”, “alanine aminotransferase”, “cardiac glycosides”); the plain phrasing in at_a_glance is required by 7.4 and mirrors the ER Conclusion.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All verified byte-identical to [qrs_template]: lines 445, 491, 541, 640, 669, 838, 576, 602, 673–675, and the four tier labels in both tier lists.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 named template spans present; the repeatable marker_#_* and qualitative_item_# spans are instantiated as marker_1–marker_10 and qualitative_item_1–qualitative_item_6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three <span website="..."> elements (evidence_review, audit, full_review) and all surrounding markup, CSS and the footer disclaimer are unchanged from the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section drawn on by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels match the ER bullets verbatim (“European regulated laxative dose”, “Best time of day”, “Single versus split dosing”); all ten interaction labels match their ER bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	All ten marker_#_name values reproduce the ER biomarker-table names exactly; no label is shortened or coined.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; the ER’s “⚠️ Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than extended: tier lists are semicolon-joined noun phrases, gate items are stripped to the key fact, and the cadence paragraph compresses the ER’s monitoring paragraph. No second page or extra card was added.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1, before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the “QRS — Metadata” caption precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are repeated in the header or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: chinese_rhubarb_2026-0904-0219_Opus_ER.md, matching the ER’s own filename field.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge of [qrs_prompt].
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0904-0552, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Chinese Rhubarb for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Chinese Rhubarb for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/04/2026, correctly derived from qrs_creation_date: 2026-0904-0552.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block is identical to the template apart from the three substituted spans; the ER’s alternate-names line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three strands of the ER Conclusion: the one validated use, the conflicted wider claims, and the duration-driven harm profile.
7.2	[at_a_glance] is no longer than 60 words	🟢	53 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“one narrow, well-supported job”, “European medicines regulators accept it”, “whose clinical income and standing depend on the answer” and “harms scale with how long it is taken rather than with dose alone” all appear in the ER Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “kidney failure”, “hospital care”, “weak trials” are used in place of the ER’s clinical terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map one-to-one onto the ER’s “Populations who should avoid Chinese Rhubarb” list (ER lines 355–363).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All nine ER avoid-populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Nine <li> elements inside the stop_items span (lines 579–597).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s explanatory gloss “(a bowel that has lost its muscular activity)” was stripped from the intestinal-atony item; no item carries a trailing dash clause.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(Child-Pugh Class B or C)”, “(filtration rate below 30 mL/min/1.73 m²)”, “below 3.5 mmol/L”, “above 40 mg”, “below 4.0 mmol/L” and “under 12 years of age” all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names nine such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map one-to-one onto the ER’s interaction bullets (ER lines 333–351).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interactions carried; the cardiac-glycoside entry is broader than the narrower “digoxin with potassium below 4.0 mmol/L” contraindication, so it is not a duplicate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten <li> elements inside the caution_items span (lines 605–630).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every mechanism sentence and “Mitigation:” clause from the ER bullets was dropped; the gloss “the heart’s electrical recovery time” was correctly stripped from the QT item.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All ER example-drug lists preserved verbatim, including “(furosemide, hydrochlorothiazide, indapamide)”, “(amiodarone, sotalol, quinidine)” and “(senna, cascara sagrada, aloe latex, bisacodyl, magnesium citrate, high-dose vitamin C)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten such interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map onto bullets of the ER Therapeutic Protocol section (ER lines 391, 405, 409).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing and dose-splitting — the three bullets a self-directed user can act on; the hospital and pharmacopoeial doses and the competing-approach bullets are not self-administrable.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: “20–30 mg”, “Evening” and “Single dose” with subs carrying the ER’s rhein basis, age and duration limits, food timing and hospital-protocol caveat.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Laxation (6–12 hours) and kidney markers (weeks to months) come from the ER Practical Considerations time-to-effect bullet; the six-month cholesterol/endothelial window comes from the ER’s single atherosclerosis trial.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High, High, Medium: constipation relief and kidney markers are High-tier benefits, the LDL/endothelial effect is Medium-tier.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are available in the ER; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; each sub traces to ER text (bacterial conversion delay, fourfold creatinine reduction with long-term dosing, six-month trial outcomes).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All thirteen entries correspond to the thirteen #### benefit headings of the ER Expected Benefits section.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated, matching the ER’s High/Medium/Low/Speculative tiering exactly (5/1/3/4 items).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER benefit heading reduced to a noun phrase; no **Magnitude:** content, confidence interval or trial count carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven entries correspond to the eleven #### risk headings of the ER Potential Risks & Side Effects section.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated, matching the ER tiering exactly (1/3/5/2 items).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER risk heading reduced to a noun phrase; no odds ratios, percentages or cohort details carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER Monitoring Protocol & Defining Success biomarker table (ER lines 486–497).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarkers listed in ER order, with the “Optimal Functional Range” and “Why Measure It?” columns reproduced exactly and the “Context/Notes” column correctly dropped.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated with the ER’s baseline, one-week, four-week, three-to-six-month and twelve-week intervals condensed into four sentences.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Taken from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list (ER lines 501–506).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers listed verbatim and in ER order.

Issues 04/09/2026 06:00

Pass rate 100.00%. No issues found.